Hayden Royal’s Lexicon Pharmaceuticals LXRX Stock Holding History

Hayden Royal’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-15,480	Closed	-$88.5K	–	222
2020 Q2	$88.5K	Buy	+15,480	New	+$30.3K	0.05%	159

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Hayden Royal's LXRX Position: Q3 2020 in Review

Hayden Royal sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2020, closing a stake of 15,480 shares — an estimated $88.5K sold.

Hayden Royal first reported a position in LXRX in Q2 2020 and held it in 1 quarter. The position peaked at $88.5K in Q2 2020. 91 funds tracked by Wall St. Rank hold LXRX as of Q3 2020.

Hayden Royal reported no remaining Lexicon Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Hayden Royal sold 15,480 Lexicon Pharmaceuticals shares in Q3 2020, an estimated $88.5K.
Hayden Royal first reported a position in Lexicon Pharmaceuticals in Q2 2020 and held it in 1 quarter.
Hayden Royal's Lexicon Pharmaceuticals position peaked at $88.5K in Q2 2020.
91 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2020.

Based on Hayden Royal's 13F filing for Q3 2020, filed 6 Nov 2020.